The New York Times reports:
A Johnson & Johnson booster shot provided strong protection against the Omicron variant, greatly reducing the risk of hospitalization, according to a clinical trial in South Africa.
The study, which compared more than 69,000 boosted health care workers with a corresponding group of unvaccinated South Africans, found that two shots of the vaccine reduced the risk of hospitalization from Omicron by about 85 percent.
In comparison, another study in South Africa found that two shots of the Pfizer-BioNTech vaccine reduced the risk of hospitalization by about 70 percent.
Read the full article.
Breaking News: Johnson & Johnson’s booster shot offered strong protection against Omicron and reduced the risk of hospitalization, a clinical trial found. https://t.co/LdGPoPHfXV
— The New York Times (@nytimes) December 30, 2021